OJSC “VEROPHARM” announces financial results for the first nine months and the 3rd quarter of 2011 year (unaudited)

28.12.2011

DECEMBER 28, 2011, MOSCOW — OJSC “VEROPHARM” [RTS:VRPH, MICEX:VFRM] announces its unaudited financial results for the first nine months and the third quarter of 2011 in accordance with the International Financial Reporting Standards (IFRS).

Sales

RUR 4,534.1 million — sales of Veropharm’s finished goods in the nine months of 2011, up 15.3% as compared to the nine months of 2010; ^[1]
RUR 4,381.7 million — sales in the domestic market was 3.4% of the total Company’s sales for the nine months of 2011;
RUR 102.7 million — Veropharm sales as part of the Federal Reimbursement Program (FRP) accounted for 2.3% of the Company’s sales during nine months of 2011.

Pharmaceutical products sales amounted to RUR 3,785.6 million in 9M 2011, a 14.9% increase in comparison with 9M 2010. Sales in the third quarter of 2011 compared to third quarter 2010 grew by 9.5% and amounted to RUR 1,189.9 million, including:

Rx drugs sales amounted to RUR 3,184.4 million in 9M 2011, a 15,4% increase in comparison with 9M 2010. The Rx drugs sales accounted for 70,2% of total finished goods sales.
In 9M 2011 traditional drug sales amounted to RUR 22.5 million and made up 0,5% of total finished goods sales.
OTC drugs sales amounted to RUR 578.7 million in 9M 2011, a 16,4% increase in comparison with 9M 2010. The share of OTC drugs sales accounted for 12,8% of total finished goods sales.

Non-pharmaceutical products (adhesive bandages and cosmetic products) sales came to RUR 748.5 million, a 17,2% increase in comparison with 9M 2010. The share of adhesive bandages and cosmetic products in total finished goods sales of the Company was 16,5%. 9.0% increase in comparison with 3Q 2010.

Core operating profit during nine months of 2011 amounted to RUR 1,232.6 million, in the line with increase in revenues and up to 17.6%.
Operating margin for the nine months increased by 2,1%.
EBITDA for the nine months of 2011 was RUR 1,338.1 million, a 17,4% increase in comparison with the same period in 2010.
EBITDA margin was up to 1,9%.
Net profit for the nine months of 2011 was RUR 1,158.0 million, a 38,9% increase.
Net profit margin increased by 20,5% compared to the nine months of 2010.

Debt

At the end of 9M 2011 Veropharm’s debt came to RUR 979.1 million, that represents less than 20% of net assets.

Equity

The Veropharm general shareholders meeting has decided to allocate RUR 190 million of 2010 dividends.

^[1] — % as percentage of finished goods sales

(PDF, 457,85 КБ)

Press-release